Clinical Trials Directory

Trials / Terminated

TerminatedNCT02711735

Safety of RUTI® Vaccination in MDR-TB Patients

Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients With MDR-TB After Successful Intensive-phase Treatment.

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
9 (actual)
Sponsor
Archivel Farma S.L. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIa trial to evaluate safety and immunogenicity of RUTI® vaccine in Multidrug-resistant Tuberculosis (MDR-TB) patients favourably responding to standard MDR-TB treatment. Time point of vaccination starts at 16 weeks upon start of standard MDR-TB treatment (cohort A), and if clinically safe as evaluated by an independent panel of experts (DSMB), another cohort of patients will be vaccinated at 2 weeks upon start of standard MDR-TB treatment (cohort B), All the patients will be followed up 8 weeks after vaccination.

Detailed description

Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIa trial to evaluate safety and immunogenicity of RUTI® vaccine in Multidrug-resistant Tuberculosis (MDR-TB) patients favourably responding to standard MDR-TB treatment. Time point of vaccination starts at 16 weeks upon start of standard MDR-TB treatment (cohort A), and if clinically safe as evaluated by an independent panel of experts (DSMB), another cohort of patients will be vaccinated at 2 weeks upon start of standard MDR-TB treatment (cohort B)

Conditions

Interventions

TypeNameDescription
BIOLOGICALRUTI® Therapeutic vaccineParticipants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
BIOLOGICALMatching RUTI® PlaceboParticipants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid

Timeline

Start date
2020-03-18
Primary completion
2020-09-09
Completion
2020-09-09
First posted
2016-03-17
Last updated
2022-07-05

Locations

3 sites across 1 country: Ukraine

Source: ClinicalTrials.gov record NCT02711735. Inclusion in this directory is not an endorsement.